Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2

Area of Science:

• Gynecologic Oncology
• Genetics
• Preventive Medicine

Background:

• Ovarian cancer (OC) is a leading cause of cancer death in women.
• Germline mutations in Breast Cancer Susceptibility Genes 1 and 2 (BRCA1/2) increase OC risk 20-40 fold.
• BRCA-associated OC is often diagnosed late, lacking effective mortality-reducing screening.

Purpose of the Study:

• To review current pharmacologic interventions for gynecologic malignancy risk reduction in BRCA 1/2 mutation carriers.
• To summarize surgical risk-reducing strategies for BRCA 1/2 mutation carriers.
• To provide an up-to-date overview of options for managing elevated OC risk.

Main Methods:

• Literature review of pharmacologic risk-reducing interventions.
• Review of surgical risk-reducing interventions.
• Synthesis of current research on BRCA-associated gynecologic malignancy.

Main Results:

• Pharmacologic options include oral contraceptive pills, acetylsalicylic acid/nonsteroidal anti-inflammatory drugs (ASA/NSAID) therapy, and denosumab.
• Surgical options include risk-reducing bilateral salpingo-oophorectomy, salpingectomy with delayed oophorectomy, and hysterectomy.
• These interventions aim to mitigate the increased risk of gynecologic cancers in mutation carriers.

Conclusions:

• Multiple pharmacologic and surgical strategies are available for risk reduction in BRCA 1/2 mutation carriers.
• These interventions are crucial for managing the significantly elevated risk of ovarian and other gynecologic cancers.
• Further research and personalized approaches are essential for optimizing risk management.